Short answer
RxSight, Inc. (RXST) filed an 8-K current report with the SEC on July 6, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item EX-99.1 (Exhibit EX-99.1). Preliminary unaudited second-quarter financial and operational results announced July 6, 2026.
RxSight, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Preliminary unaudited second-quarter financial and operational results announced July 6, 2026
- Results cover fiscal Q2 2026; investors should review Exhibit 99.1 for disclosed figures and metrics
- Preliminary status means reported results remain subject to completion of quarter-end procedures and potential adjustments
Item EX-99.1 · Exhibit EX-99.1
- Preliminary Q2 revenue $32–$34M, including $5–$7M from the Alcon collaboration
- Core sales approximately $27M, including 24,917 LAL units and 11 LDD units
- Cash, equivalents and short-term investments approximately $209M as of June 30, 2026
- 2026 sales guidance cut to $110–$120M from $120–$135M amid commercial headwinds
- Full-year revenue $140–$160M and gross margin raised to 73%–75%, reflecting expected collaboration revenue and favorable mix
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other RxSight, Inc. 8-K filings
Get the next RXST 8-K as it lands
Follow RXST for push alerts, or ask the research agent what this filing means.